濟川藥業(600566.SH)：子公司簽署伊坦生長激素(TJ101)獨家開發、生產及銷售合作協議
格隆匯11月10日丨濟川藥業(600566.SH)公佈，公司全資子公司濟川藥業集團有限公司、江蘇濟源醫藥有限公司(以下合稱“公司方”)與I-MAB BIOPHARMA HONGKONG LIMITED 天境生物科技香港有限公司(“天境香港”)、天境生物科技(上海)有限公司(以下合稱“天境生物”)達成戰略合作協議，天境生物許可公司方在中華人民共和國大陸地區(不包括香港特別行政區、澳門特別行政區和台灣)進行天境生物長效重組人生長激素伊坦生長激素(以下簡稱“TJ101”、“目標產品”)的開發、生產及商業化。
公司支付的首付款及里程碑付款將不超過人民幣20.16億元(不含税)。
伊坦生長激素是一種具有高度差異化的長效重組人生長激素，有望成為一種更安全便捷有效的生長激素缺乏症替代療法。與內源性生長激素一致，伊坦生長激素可刺激胰島素樣促生長因子1(IGF-1)在肝臟中的合成，並激發包括成骨細胞和軟骨細胞在內的多種組織的生長刺激作用，以促進骨骼的生長。
IGF-1是可靠的藥效學標誌物，也是伊坦生長激素促生長活性的關鍵介質。伊坦生長激素基於Genexine的專利hyFc®技術開發，hyFc部分由人免疫球蛋白D(IgD)和G4(IgG4)的一部分組成。前者包含一個柔性鉸鏈，後者可通過新生兒Fc受體(FcRn)介導的代謝調控延長半衰期。
截止目前，獲得重組人生長激素中國上市許可的企業有7家，國內企業5家，進口企業2家。其中長效生長激素製劑僅有1家，為長春金賽藥業有限責任公司生產的聚乙二醇重組人生長激素注射液。
根據Frost&Sullivan的市場研究報吿，2020年全國重組人生長激素銷售總額約59億元，其中聚乙二醇重組人生長激素注射液銷售額在6億左右。
本次交易完成後，公司將進一步加強產品線的豐富程度，充分發揮兒科治療領域的優勢培育新的業績增長點，從而提升公司的整體盈利能力和兒科治療領域的行業地位，符合公司的發展戰略和長遠利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
